Laura Deming became obsessed with aging biology at 8, joined a UCSF aging lab at 12, and founded The Longevity Fund at 17 after dropping out of MIT to become one of the youngest specialist investors in aging biotech. She maintains unusual depth across basic biology and venture investing, treating aging as an engineering problem while building the longevity field through her technical FAQ documenting 95+ lifespan-extending interventions and her focus on achieving the first regulatory recognition of lifespan extension therapies. Laura Deming became obsessed with aging biology at 8, joined a UCSF aging lab at 12, and founded The Longevity Fund at 17 after dropping out of MIT to become one of the youngest specialist investors in aging biotech. She maintains unusual depth across basic biology and venture investing, treating aging as an engineering problem while building the longevity field through her technical FAQ documenting 95+ lifespan-extending interventions and her focus on achieving the first regulatory recognition of lifespan extension therapies.